Cognition Therapeutics, Inc., a Pittsburgh, PA-based drug discovery company focused on neurodegenerative disorders, raised $138k in funding.
Founded in 2007 by Susan Catalano, Ph.D., Chief Science Officer, Gilbert M. Rishton, Ph.D., Chief Medicinal Chemistry Advisor, and Franz F. Hefti, Ph.D., Director, and led by Hank Safferstein, Ph.D., JD., Chief Executive Officer, Cognition Therapeutics uses proprietary and biologically-relevant screening technology to discover novel drug targets and disease modifying therapies for disorders of the central nervous system.
The company’s biology and chemistry platforms have delivered drugs that selectively block soluble Abeta oligomer- induced toxicity on synapses without affecting normal Abeta expression or function. Mechanism of action studies on these proprietary drugs have revealed a number of novel strategies to target receptors and pathways central to the pathology of Alzheimer’s disease.
20/01/2011: Cognition Therapeutics Closes $2.5M Series A1 Financing